162 related articles for article (PubMed ID: 20714935)
1. Emergence of secondary resistance to imatinib in recurrent gastric GIST.
Jayanthi NV
J Gastrointest Surg; 2010 Dec; 14(12):2018-9; author reply 2020. PubMed ID: 20714935
[No Abstract] [Full Text] [Related]
2. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
3. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
Lai IR; Hu RH; Chang KJ
Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
[TBL] [Abstract][Full Text] [Related]
4. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
5. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.
Bickenbach K; Wilcox R; Veerapong J; Kindler HL; Posner MC; Noffsinger A; Roggin KK
J Gastrointest Surg; 2007 Jun; 11(6):758-66. PubMed ID: 17417711
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
[TBL] [Abstract][Full Text] [Related]
7. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.
Salazar M; Barata A; André S; Venâncio J; Francisco I; Cravo M; Nobre-Leitão C
Gut; 2006 Apr; 55(4):585-6. PubMed ID: 16531543
[No Abstract] [Full Text] [Related]
8. [A case of an elderly patient with recurrent GIST, which was effectively treated with low-dose imatinib mesylate].
Matsumoto S; Takahashi M; Ishizu H; Takahashi H; Masuko H; Tanaka K; Hata T; Yamagami H; Takahashi S; Tahara M; Ueki S; Kuji M; Tanioka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2405-7. PubMed ID: 25731538
[TBL] [Abstract][Full Text] [Related]
9. [Long-Term Survival by Low-Dose Imatinib after Recurrence of GIST].
Mihara Y; Ando T; Hayashi M; Atsuta K; Nakayama T; Isobe K
Gan To Kagaku Ryoho; 2022 Jan; 49(1):63-65. PubMed ID: 35046364
[TBL] [Abstract][Full Text] [Related]
10. Recurrent GI bleeding and surgery following the initial response to imatinib therapy in GIST of the stomach.
El Hajj II; Chehal A; El Saghir NS
Dig Dis Sci; 2005 Jan; 50(1):65-9. PubMed ID: 15712639
[No Abstract] [Full Text] [Related]
11. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
[TBL] [Abstract][Full Text] [Related]
12. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
13. [STI571 for gastrointestinal stromal tumors].
Nakanishi M; Noguchi A; Takeshita H; Yamamoto Y; Ito T; Tani N; Suganuma Y; Yamaguchi M; Okano S; Yamane T
Nihon Shokakibyo Gakkai Zasshi; 2006 Jul; 103(7):819-26. PubMed ID: 16869383
[TBL] [Abstract][Full Text] [Related]
14. Reintroduction of imatinib in GIST.
Reid T
J Gastrointest Cancer; 2013 Dec; 44(4):385-92. PubMed ID: 23921604
[TBL] [Abstract][Full Text] [Related]
15. Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Shankar S; Dundamadappa SK; Karam AR; Stay RM; van Sonnenberg E
Acta Radiol; 2009 Oct; 50(8):837-44. PubMed ID: 19735005
[TBL] [Abstract][Full Text] [Related]
16. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.
Gronchi A; Raut CP
Ann Surg Oncol; 2012 Apr; 19(4):1051-5. PubMed ID: 22207052
[No Abstract] [Full Text] [Related]
17. Adjuvant imatinib for GIST: the pie is shrinking.
Balachandran VP; DeMatteo RP
Ann Surg Oncol; 2014 Oct; 21(11):3365-6. PubMed ID: 25120253
[No Abstract] [Full Text] [Related]
18. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
[TBL] [Abstract][Full Text] [Related]
19. Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
Ulusan S; Koç Z; Kayaselçuk F
Turk J Gastroenterol; 2008 Jun; 19(2):129-32. PubMed ID: 19110671
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumors: current management.
Pisters PW; Patel SR
J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
